Perancangan Aplikasi Akuntansi Pelayanan Apotek pada Apotek Ating XI Bandung

Teknologi informasi berkembang sangat pesat, salah satu perangkat yang terkena adalah komputer. Dari waktu ke waktu ada kemajuan pada perangkat ini kedua perangkat lunak dan perangkat keras. Apotek Ating XI yang sampai sekarang belum terkomputerisasi dan benar-benar membutuhkan aplikasi untuk mendukung dan memberikan pelayanan yang memuaskan kepada konsumen dan untuk mendukung pembuatan laporan lebih cepat, akurat, efektif dan efisien. Apotek Ating XI adalah Perusahaan yang bergerak di bidang penjualan obatobatan dan alat kesehatan. Pencatatan transaksi mulai dari pembelian barang, penjualan barang dan pembuatan laporan masih dilakukan secara manual sehingga rentan terjadi kesalahan selama proses transaksi berlangsung. Kurangnya aplikasi komputer membuat transaksi sedikit terhambat, terutama dalam hal laporan keuangan. Metode pengumpulan data yang digunakan, yaitu, observasi, wawancara, dan sastra. Desain aplikasi akuntansi ini adalah solusi terbaik untuk memecahkan masalah dan kendala yang terjadi di Perusahaan ini untuk masukan proses pembelian, proses penjualan barang dan pelaporan proses bisa berjalan lebih cepat dan yang paling penting, laporan dapat dihasilkan lebih akurat . Dengan desain aplikasi akuntansi Perusahaan ini diharapkan dapat dikembangkan lebih lanjut di tengah tigh persaingan di dunia bisnis saat in

AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression

Gene transfer vectors based on the adeno-associated virus (AAV) are used for various experimental and clinical therapeutic approaches. In the present study, we demonstrate the utility of rAAV as a tumoricidal agent in human colorectal cancer. We constructed an rAAV vector that expresses tumor necrosis factor (TNF)-related apoptosis-inducing figand (TRAIL/Apo2L) and used it to transduce human colorectal cancer cells. TRAIL belongs to the TNF superfamily of cytokines that are involved in various immune responses and apoptotic processes. It has been shown to induce cell death specifically in cancer cells. Transduction with AAV.TRAIL gave rise to rapid expression of TRAIL, followed by induction of apoptosis, which could be inhibited by the caspase inhibitor z-VAD.fmk, in several human colon cancer cell lines. The apoptotic mechanism included activation of caspase-3, as well as cytochrome c release from mitochondria. The outgrowth of human colorectal tumors grown in mice was completely blocked by transduction with AAV.TRAIL in vitro, while in vivo transduction significantly inhibited the growth of established tumors. AAV vectors could provide a safe method of gene delivery and offer a novel method of using TRAIL as a therapeutic protein. © 2004 Nature Publishing Group All rights reserved

AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression

Gene transfer vectors based on the adeno-associated virus (AAV) are used for various experimental and clinical therapeutic approaches. In the present study, we demonstrate the utility of rAAV as a tumoricidal agent in human colorectal cancer. We constructed an rAAV vector that expresses tumor necrosis factor (TNF)-related apoptosis-inducing figand (TRAIL/Apo2L) and used it to transduce human colorectal cancer cells. TRAIL belongs to the TNF superfamily of cytokines that are involved in various immune responses and apoptotic processes. It has been shown to induce cell death specifically in cancer cells. Transduction with AAV.TRAIL gave rise to rapid expression of TRAIL, followed by induction of apoptosis, which could be inhibited by the caspase inhibitor z-VAD.fmk, in several human colon cancer cell lines. The apoptotic mechanism included activation of caspase-3, as well as cytochrome c release from mitochondria. The outgrowth of human colorectal tumors grown in mice was completely blocked by transduction with AAV.TRAIL in vitro, while in vivo transduction significantly inhibited the growth of established tumors. AAV vectors could provide a safe method of gene delivery and offer a novel method of using TRAIL as a therapeutic protein. © 2004 Nature Publishing Group All rights reserved